Zacks Research Estimates Perrigo’s Q1 Earnings (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) – Analysts at Zacks Research decreased their Q1 2027 earnings per share (EPS) estimates for shares of Perrigo in a report issued on Monday, March 23rd. Zacks Research analyst Team now anticipates that the company will earn $0.68 per share for the quarter, down from their previous estimate of $0.69. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2027 earnings at $0.54 EPS, FY2027 earnings at $2.51 EPS and FY2028 earnings at $2.57 EPS.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.77 EPS for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The firm’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the firm earned $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

PRGO has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Argus upgraded Perrigo to a “hold” rating in a research report on Wednesday, January 14th. JPMorgan Chase & Co. lowered their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Finally, Canaccord Genuity Group dropped their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, February 27th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $19.33.

Perrigo Stock Performance

Shares of NYSE:PRGO opened at $9.65 on Tuesday. Perrigo has a 1 year low of $9.23 and a 1 year high of $28.43. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -0.94, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63. The company’s 50 day simple moving average is $13.07 and its 200 day simple moving average is $15.82.

Perrigo Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 24th. Investors of record on Monday, March 2nd were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 12.0%. The ex-dividend date was Monday, March 2nd. Perrigo’s dividend payout ratio (DPR) is -11.28%.

Institutional Investors Weigh In On Perrigo

Institutional investors have recently added to or reduced their stakes in the business. Amundi increased its position in Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares during the period. Slocum Gordon & Co LLP grew its stake in shares of Perrigo by 1.1% in the third quarter. Slocum Gordon & Co LLP now owns 53,253 shares of the company’s stock worth $1,186,000 after purchasing an additional 602 shares during the last quarter. Kestra Investment Management LLC grew its stake in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares during the last quarter. State of Wyoming increased its holdings in Perrigo by 7.8% in the third quarter. State of Wyoming now owns 8,988 shares of the company’s stock valued at $200,000 after purchasing an additional 653 shares during the period. Finally, First Citizens Bank & Trust Co. raised its position in Perrigo by 4.7% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 17,323 shares of the company’s stock worth $386,000 after purchasing an additional 775 shares during the last quarter. 95.91% of the stock is owned by institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.